Akari Therapeutics shared its third quarter results and announced new studies for its cancer treatment, AKTX-101.

Nov 12, 2026, 5:23 PM ETResultsRead the original at SEC EDGAR

Good for AKTX

Akari began safety studies for its lead drug and reported activity in models resistant to existing ADC treatments, bringing the drug closer to human testing. Its planned 2027 trial still depends on getting more funding.

AKTX · Akari Therapeutics Plc

AI read · Good for AKTX

The AI's read

These steps bring Akari’s lead drug closer to testing in people. Activity in models resistant to existing ADC treatments could give the drug an advantage. The company still needs more funding before its planned human study can begin.

Get alerts for AKTX

Follow Akari Therapeutics Plc (AKTX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for AKTX

Free on the App Store and Google Play, or on the web.